JP2016535071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535071A5 JP2016535071A5 JP2016543477A JP2016543477A JP2016535071A5 JP 2016535071 A5 JP2016535071 A5 JP 2016535071A5 JP 2016543477 A JP2016543477 A JP 2016543477A JP 2016543477 A JP2016543477 A JP 2016543477A JP 2016535071 A5 JP2016535071 A5 JP 2016535071A5
- Authority
- JP
- Japan
- Prior art keywords
- fxa variant
- variant protein
- composition
- acid sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881834P | 2013-09-24 | 2013-09-24 | |
| US61/881,834 | 2013-09-24 | ||
| PCT/IB2014/064564 WO2015044836A1 (en) | 2013-09-24 | 2014-09-16 | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535071A JP2016535071A (ja) | 2016-11-10 |
| JP2016535071A5 true JP2016535071A5 (enExample) | 2017-10-12 |
| JP6429885B2 JP6429885B2 (ja) | 2018-11-28 |
Family
ID=51844797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016543477A Expired - Fee Related JP6429885B2 (ja) | 2013-09-24 | 2014-09-16 | 組換えヒト凝固第ｘａ因子タンパク質の不均一集団を含む組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9757434B2 (enExample) |
| EP (1) | EP3049434A1 (enExample) |
| JP (1) | JP6429885B2 (enExample) |
| KR (1) | KR101988705B1 (enExample) |
| CN (2) | CN112195169A (enExample) |
| AR (1) | AR097732A1 (enExample) |
| AU (1) | AU2014326257B2 (enExample) |
| BR (1) | BR112016005899A8 (enExample) |
| CA (1) | CA2924981C (enExample) |
| HK (1) | HK1218760A1 (enExample) |
| IL (2) | IL244258A0 (enExample) |
| MX (1) | MX373466B (enExample) |
| MY (1) | MY173548A (enExample) |
| PE (1) | PE20160877A1 (enExample) |
| RU (1) | RU2648144C2 (enExample) |
| SA (1) | SA516370751B1 (enExample) |
| SG (1) | SG11201601221XA (enExample) |
| TW (1) | TWI631134B (enExample) |
| WO (1) | WO2015044836A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1215196A1 (zh) | 2013-01-31 | 2016-08-19 | 辉瑞公司 | 用於抵消因子xa抑制的组合物和方法 |
| CN112195169A (zh) | 2013-09-24 | 2021-01-08 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
| EP3926044B1 (en) | 2016-06-17 | 2025-06-04 | Alexion Pharmaceuticals, Inc. | Preparation of factor xa derivatives |
| EP3722418A1 (en) * | 2019-04-08 | 2020-10-14 | AB Enzymes Oy | Solution stable enzyme composition |
| EP4127158A2 (en) * | 2020-04-02 | 2023-02-08 | Takeda Pharmaceutical Company Limited | Adamts13 variant, compositions, and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| AU2001249389A1 (en) | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| RU2396347C2 (ru) * | 2004-08-17 | 2010-08-10 | Ксл Бехринг Гмбх | Модифицированные витамин к-зависимые полипептиды |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| KR102069498B1 (ko) * | 2007-09-28 | 2020-01-23 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법 |
| US8329871B2 (en) | 2008-06-24 | 2012-12-11 | Octapharma Ag | Process of purifying coagulation factor VIII |
| CA2743496C (en) * | 2008-11-14 | 2018-03-27 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
| JP5833448B2 (ja) | 2008-12-19 | 2015-12-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用 |
| EP2453910B1 (en) | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
| PT2591006T (pt) * | 2010-07-09 | 2019-07-29 | Bioverativ Therapeutics Inc | Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas |
| FR2972114B1 (fr) | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| JP6514893B2 (ja) | 2011-09-30 | 2019-05-15 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | 止血を調節するための組成物および方法 |
| KR102049900B1 (ko) | 2012-07-25 | 2019-11-28 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 변형 인자 x 폴리펩티드 및 이의 용도 |
| HK1215196A1 (zh) | 2013-01-31 | 2016-08-19 | 辉瑞公司 | 用於抵消因子xa抑制的组合物和方法 |
| CN112195169A (zh) | 2013-09-24 | 2021-01-08 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
| US20160235824A1 (en) | 2013-11-01 | 2016-08-18 | The Children's Hospital Philadelphia | Compositions and Methods for Increasing the Half-Life of Factor XA |
| CN105934250A (zh) | 2014-01-24 | 2016-09-07 | 辉瑞公司 | 治疗脑内出血的组合物和方法 |
-
2014
- 2014-09-16 CN CN202011112690.1A patent/CN112195169A/zh active Pending
- 2014-09-16 KR KR1020167007373A patent/KR101988705B1/ko not_active Expired - Fee Related
- 2014-09-16 WO PCT/IB2014/064564 patent/WO2015044836A1/en not_active Ceased
- 2014-09-16 SG SG11201601221XA patent/SG11201601221XA/en unknown
- 2014-09-16 PE PE2016000398A patent/PE20160877A1/es unknown
- 2014-09-16 RU RU2016108608A patent/RU2648144C2/ru active
- 2014-09-16 CN CN201480052212.2A patent/CN105579468A/zh active Pending
- 2014-09-16 CA CA2924981A patent/CA2924981C/en not_active Expired - Fee Related
- 2014-09-16 JP JP2016543477A patent/JP6429885B2/ja not_active Expired - Fee Related
- 2014-09-16 HK HK16106674.2A patent/HK1218760A1/zh unknown
- 2014-09-16 BR BR112016005899A patent/BR112016005899A8/pt not_active IP Right Cessation
- 2014-09-16 MY MYPI2016700985A patent/MY173548A/en unknown
- 2014-09-16 MX MX2016003871A patent/MX373466B/es active IP Right Grant
- 2014-09-16 EP EP14792595.2A patent/EP3049434A1/en not_active Withdrawn
- 2014-09-16 AU AU2014326257A patent/AU2014326257B2/en not_active Ceased
- 2014-09-23 TW TW103132803A patent/TWI631134B/zh not_active IP Right Cessation
- 2014-09-23 AR ARP140103512A patent/AR097732A1/es unknown
- 2014-09-24 US US14/495,478 patent/US9757434B2/en not_active Expired - Fee Related
-
2016
- 2016-02-23 IL IL244258A patent/IL244258A0/en unknown
- 2016-03-17 SA SA516370751A patent/SA516370751B1/ar unknown
-
2017
- 2017-08-04 US US15/669,340 patent/US10660946B2/en active Active
-
2020
- 2020-05-25 US US16/882,598 patent/US20210106658A1/en not_active Abandoned
- 2020-12-13 IL IL279396A patent/IL279396A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Molino et al. | Different types of aqueous two‐phase systems for biomolecule and bioparticle extraction and purification | |
| DK2537862T3 (en) | A method of purifying coagulation factor VIII | |
| EP3040346B1 (en) | Process for the purification of granulocyte colony stimulating factor, g-csf | |
| FI4011908T3 (fi) | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät | |
| RU2596408C2 (ru) | Способ очистки человеческого фактора, стимулирующего колонии гранулоцитов, из рекомбинантных е. coli | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| AR080942A1 (es) | Produccion de proteinas heteromultimericas | |
| CN101616930B (zh) | 疏水性蛋白质的纯化方法 | |
| EP3325614A1 (en) | Methods for purifying adenovirus vectors | |
| JP2017505620A5 (enExample) | ||
| JP2014507368A5 (enExample) | ||
| US8536302B2 (en) | Dockerin polypeptide and method of purifying recombinant fused protein using the same | |
| CN101260145A (zh) | 一种重组人血清白蛋白及其融合蛋白的分离纯化工艺 | |
| CN104136121A (zh) | 减少离子交换色谱中的pH漂移 | |
| JP2015536347A5 (enExample) | ||
| RU2016108608A (ru) | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ГЕТЕРОГЕННЫЕ ПОПУЛЯЦИИ РЕКОМБИНАНТНЫХ БЕЛКОВ ЧЕЛОВЕЧЕСКОГО ФАКТОРА СВЕРТЫВАНИЯ КРОВИ Ха | |
| JP2016538261A (ja) | ダルベポエチンアルファの精製方法 | |
| Chu et al. | High-throughput process development for recombinant human serum albumin separation from Pichia pastoris broth with mixed-mode chromatography | |
| CN102675445A (zh) | 一种类泛素修饰蛋白及其制备和应用 | |
| CN102443055B (zh) | 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺 | |
| Schirmer et al. | Reduction of product‐related species during the fermentation and purification of a recombinant IL‐1 receptor antagonist at the laboratory and pilot scale | |
| CN110831956A (zh) | 重组蛋白 | |
| Misterova et al. | Optimization of a Purification Method for the Recombinant Platelet-Derived Growth Factor rhPDGF-BB Expressed in the Methylotrophic Yeast Pichia Pastoris | |
| RU2528061C1 (ru) | Способ получения цитохрома с | |
| JP2001139600A (ja) | Ｉｌ−６ｒ・ｉｌ−６融合蛋白質の精製方法 |